Engflag

Nomi

Quick links to important sections

Nomi

Nomi_EN

Method of action: Analgesic, Antimigraine

Treatment option: Headache, Migraine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nomi

Property Description
Active ingredient Zolmitriptan
Form Tablet (Film-coated, ODT), Nasal spray
Pharmacological class Triptan, Selective Serotonin Receptor Agonist
Common use Acute treatment of migraine headaches
Origin Synthetic

Nomi (Zolmitriptan): Definition and Pharmacological Class

Nomi is the trade name for the synthetic, prescription-only medicine with the international non-proprietary name (INN) of Zolmitriptan. It belongs to a specialized group of antimigraine agents known as triptans. This drug is classified as a selective serotonin receptor agonist that works by targeting the 5-HT1B and 5-HT1D receptor subtypes in the body, distinguishing it from general pain relievers like NSAIDs. This mechanism is recognized for addressing the neurological and vascular changes characteristic of a migraine.

Zolmitriptan is indicated for the acute treatment of migraine with or without aura, highlighting its specific, targeted therapeutic role.

Composition, Available Forms, and General Purpose

The core component of Nomi is the single active ingredient Zolmitriptan, which is subsequently metabolized in the body into an active substance, the N-desmethyl metabolite. This composition is notable for its versatility, as Nomi is available in multiple pharmaceutical preparations to accommodate different patient needs. These forms include a standard oral film-coated tablet, an orally disintegrating tablet (ODT), and a metered-dose nasal spray. The availability of both oral and intranasal routes is a key differentiating feature, offering an advantage for patients who experience severe nausea or vomiting during a migraine attack.

The efficacy of this drug class in relieving headache pain and associated symptoms often results in relief within two hours. The primary general purpose of Nomi is therefore the rapid and specific acute treatment of migraine headaches, aiming to relieve the severe throbbing pain and associated symptoms, providing a focused therapeutic intervention at the onset of an acute attack.

Regulatory References

  1. NICE Guideline on Triptans for Migraine

What side effects are possible with Nomi?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety constraints for Nomi, based strictly on government regulatory labeling (e.g., FDA, EMA).

Adverse Reaction Scope

Adverse effects are categorized by the body system affected (System-Organ Class) and their frequency of occurrence, as determined in clinical trials:

Frequency Classification Examples of Documented Side Effects
Very Common (ge 1/10) Headache, Nausea, Fatigue.
Common (ge 1/100 to < 1/10) Diarrhea, Insomnia, Dizziness.
Uncommon (ge 1/1,000 to < 1/100) Rash, Increased Liver Enzymes (ALT/AST).

System-Organ Classes Involved include Nervous System Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions

The label documents rare but clinically significant events. These Serious Adverse Reactions (SARs) may include Severe Hepatic Injury, Anaphylactic Reaction/Angioedema, and Agranulocytosis. Immediate medical attention is required for any suspected SAR.

Safety Restrictions and Monitoring

  • Contraindication: Nomi is formally contraindicated in individuals with a history of Nomi-induced Angioedema.
  • Required Monitoring: Hepatic function tests (ALT/AST) must be performed prior to treatment initiation and monthly for the first six months. The drug must be permanently discontinued if ALT/AST levels exceed three times the Upper Limit of Normal (ULN).
  • Exposure Patterns: Nausea and Diarrhea are documented as most common during the initial two weeks of therapy. The risk of Increased Liver Enzymes is stated to increase after six months of continuous therapy.

Population-Specific Safety Notes

  • Renal Impairment: Increased monitoring for systemic side effects is required for patients with severe renal impairment (Creatinine Clearance < 30 mL/min), as plasma exposure of Nomi is increased.
  • Pregnancy: Use during pregnancy should be avoided unless the potential benefit justifies the risk to the fetus, as human data are insufficient to determine drug-associated risk.

Regulatory Safety Summary: The official safety profile structures risks by incidence and severity. It explicitly documents common and rare adverse effects, establishes mandatory monitoring requirements (e.g., liver function tests), and defines the specific conditions under which the medicine cannot be used, ensuring the boundaries of safe use are clearly defined by the regulatory authority.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Nomi (Zolmitriptan) defines the overdose profile based on documented clinical manifestations and mandated emergency procedures. The information provided is strictly descriptive and non-advisory.

Documented Manifestations and Severe Risks

In cases of exposure to doses significantly higher than prescribed, the primary clinical sign explicitly documented in regulatory information is sedation. However, severe intoxication is associated with the risk of excessive vasoconstriction and resulting cardiovascular symptoms, including those consistent with ischaemic heart disease. A potentially life-threatening complication linked to excessive serotonergic activity is Serotonin Syndrome, which may involve agitation, high blood pressure, and neuromuscular instability.

When to Seek Immediate Medical Help

Emergency medical attention is required for severe intoxication. The official label mandates that if symptoms consistent with ischaemic heart disease (such as chest pain) occur, an appropriate medical evaluation must be sought immediately.

Official Management and Monitoring

Management of overdose is symptomatic and supportive, as no specific antidote is known. For severe cases, regulatory sources recommend initiating intensive care procedures. This involves establishing and maintaining a patent airway, ensuring adequate oxygenation, and providing continuous monitoring and support of the cardiovascular system due to the risk of hypertension. The severity classification points to the necessity of hospital observation.

Therapeutic Uses of Nomi

Nomi (Zolmitriptan) is commonly used for the acute symptomatic management of specific, severe neurovascular headache conditions, including migraine headaches. This approach is relevant for easing symptoms during the active phase of an attack.

It is applied in addressing conditions characterized by episodic, moderate to severe migraine headaches (with or without aura). It also helps address pronounced symptoms accompanying the headache, such as nausea, vomiting, photophobia, and phonophobia.

“The primary benefit contributes to improved comfort during periods of heightened symptoms, which assists with maintaining functional stability during phases of increased distress.”

This action provides support during phases where intense symptoms create noticeable interference with daily stability. It may also be part of symptomatic management for menstrual migraines and episodic cluster headache attacks in certain contexts.

Quick Fact: Support for Migraine Pain Nomi is relevant for easing the characteristic severe throbbing or pulsating pain, offering symptomatic relief that helps patients cope more steadily with episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Nomi?

The population eligibility for Nomi (Zolmitriptan) is strictly defined by regulatory documents, primarily based on underlying cardiovascular health, age, and organ function. The medication is an acute treatment for migraine in eligible adults.

Absolute Contraindications

Use of Nomi is contraindicated (must not be used) in patients with specific high-risk conditions, including:

  • A history of Ischemic Heart Disease (such as prior myocardial infarction or angina pectoris).
  • Uncontrolled Hypertension or certain arrhythmias (e.g., Wolff-Parkinson-White syndrome).
  • History of stroke, Transient Ischemic Attack (TIA), or specific high-risk migraines like basilar or hemiplegic migraine.
  • Recent use (within 24 hours) of another triptan or an ergotamine-containing medication.

Age and Organ Function Restrictions

Population Group Eligibility Status Regulatory Basis
Children (under 12) Not Recommended Safety and efficacy are not established.
Older Adults (over 65) Not Recommended Safety and efficacy are not established.
Severe Hepatic Impairment Conditional/Restricted Use is limited and may be contraindicated for certain forms (e.g., ODT) due to altered drug levels.
Pregnancy/Lactation Conditional Use Use during pregnancy is permitted only if the potential benefit outweighs the potential risk; caution is required during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nomi (Zolmitriptan) has officially documented interaction patterns based on governmental regulatory sources, requiring specific patient considerations and prohibitions for co-administration.

Formal Contraindications and Required Separation

The following combinations are strictly prohibited or require mandatory spacing:

  • Other 5-HT1 Agonists (Triptans): Co-administration is contraindicated. Administration must be separated by at least 24 hours.
  • Ergotamine-Containing Medications: Co-administration is contraindicated. A minimum separation of 24 hours is required before taking Nomi, or six hours after Nomi.
  • Monoamine Oxidase A (MAO-A) Inhibitors: Use of Nomi is contraindicated within two weeks of stopping a MAO-A inhibitor.

Exposure-Altering and Pharmacodynamic Interactions

Interactions are documented that affect drug concentration or introduce risk due to combined effects:

  • Cimetidine: Officially noted to increase the systemic exposure (AUC and half-life) of zolmitriptan and its active metabolite due to CYP1A2 inhibition.
  • Propranolol and Oral Contraceptives: Both are documented to cause a measurable increase in the plasma levels (Cmax and AUC) of zolmitriptan.
  • SSRIs, SNRIs, and Opioid Products: Co-administration with these serotonergic agents carries a documented risk of Serotonin Syndrome (a pharmacodynamic effect).

Other Official Cautions

  • Hepatic Impairment: Interactions may be more pronounced in cases of severe hepatic impairment, leading to higher exposure.
  • Herbal Products: St John's wort is officially noted for its potential to cause undesirable pharmacodynamic effects.

Mechanism of Action

Targeted Action on the Trigeminovascular System

Nomi (Zolmitriptan) works by acting as a highly selective agonist on two serotonin receptor subtypes: 5-HT1B and 5-HT1D. This dual agonism simultaneously targets the vascular and neural components of the affected system. The molecule engages mechanisms that influence both the caliber of certain cranial blood vessels and the signaling from sensory nerves.

Vascular Regulation and Neurotransmitter Inhibition

Activation of the 5-HT1B receptors on smooth muscle tissue initiates a cascade that causes vasoconstriction, leading to the narrowing of abnormally dilated cranial blood vessels. Concurrently, activating the 5-HT1D receptors on nerve endings acts as a prejunctional inhibitor, suppressing the release of vasoactive and inflammatory signaling molecules, such as Calcitonin Gene-Related Peptide (CGRP).

Mechanistic Contribution of the Active Metabolite

The mechanism is enhanced by the body's metabolism, which creates the N-desmethyl metabolite. This substance exhibits a significantly higher potency for the primary 5-HT1B and 5-HT1D targets than the parent drug. This internal synergy intensifies and extends the agonistic activity, which contributes to the resulting physiological modulation.

Dosage and Administration Information

How to Use Nomi (Zolmitriptan)

Zolmitriptan, marketed as Nomi, is administered through two distinct routes: oral (using tablets or orally disintegrating tablets (ODTs)) and intranasal (using a metered-dose nasal spray). The oral forms are available in 2.5 mg and 5 mg strengths, while the nasal spray is available in 2.5 mg and 5 mg single-use devices.

The medicine is intended for acute, intermittent use during a migraine episode, rather than for daily prevention. The standard recommended adult starting dose for oral forms is either 1.25 mg (obtained by breaking the scored 2.5 mg tablet) or 2.5 mg; the nasal spray typically begins at 2.5 mg. The maximum single dose across all forms is 5 mg. The administration schedule permits a single repeat dose after a minimum interval of two hours if symptoms persist or return, but the total intake must not exceed 10 mg in any 24-hour period.

Administration instructions are form-specific. The standard oral tablet may be taken with or without food. Orally Disintegrating Tablets (ODTs) are placed on the tongue to dissolve and are not intended to be split. The nasal spray is indicated for pediatric patients aged 12 years and older at a starting dose of 2.5 mg, whereas the oral tablets are not generally recommended for adolescents. Dose adjustments are necessary for specific clinical scenarios; for instance, the maximum daily dose is reduced to 5 mg for patients with moderate to severe hepatic impairment. The safety of treating more than three to four episodes per month has not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nomi

Evidence for use in Acute Migraine Treatment

Nomi (Zolmitriptan) was evaluated in studies for conditions characterized by fluctuating or episodic manifestations, specifically the acute treatment of migraine headaches in adults. Research explored the use of Nomi in carefully designed randomized, controlled trials. These studies focused on patients experiencing episodes where symptoms become more noticeable.

The researchers monitored several key outcomes related to patient-reported outcomes describing perceived discomfort and outcomes describing episodic or acute changes. This included measuring changes in headache pain intensity at defined time points in the study. Findings describe patterns observed in the studies, where patient-reported outcomes described symptom changes during the short study periods. Trials also monitored outcomes related to patient-reported outcomes describing perceived discomfort, such as nausea and increased sensitivity to light and sound, and rates of study withdrawal.

Comparing Nomi to Placebo and Other Treatments

Clinical research, primarily using placebo-controlled trials, was evaluated in settings with varying symptom burdens. In these comparative research scenarios, the studies reported how symptoms evolved in the group receiving Nomi versus the group receiving placebo. Some trials research examined sustained resolution of headache symptoms without recurrence for up to 24 hours. Comparative evidence against other acute treatments for migraine remains limited. The body of evidence helps contextualize patterns observed when comparing Nomi to an inactive treatment.

Key Gaps and Uncertainties in the Research

The research on Nomi, while comprehensive for its acute use, has specific limitations. Research provides insight into short-term changes but has not extensively monitored long-term outcomes. Long-term effects are not fully established by controlled studies regarding the frequency of use over many years. Furthermore, the characteristics of use when administering Nomi frequently are not fully established by the existing controlled trials. Research has not established the evidence patterns for sequential use of the study drug during a single episode.

Frequently Asked Questions (FAQ)

Common questions about Nomi (FAQ)

Q: What happens if I take Nomi with a MAO-A inhibitor?

Taking Nomi (Zolmitriptan) with a Monoamine Oxidase A (MAO-A) inhibitor is contraindicated, meaning it should not be used in combination. Official regulatory information shows that MAO-A inhibitors can significantly increase the concentration of Nomi's active substance in the blood. For this reason, Nomi should not be used within two weeks of stopping any MAO-A inhibitor.

Q: How long does it take for Nomi to start working?

Studies and official information indicate that Nomi is used for rapid, acute migraine treatment. In clinical trials, the headache response was often measured at the two-hour time point. For the oral forms, the medicine generally reaches a high concentration in the bloodstream within about one hour.

Q: Can Nomi be split to take a smaller dose?

Whether the medication can be split depends on the specific form. Regulatory documents indicate that the standard oral tablet (2.5 mg) is scored, and a lower 1.25 mg dose is sometimes achieved by dividing the tablet. However, the Orally Disintegrating Tablets (ODTs) are not scored and should not be broken or split.

Q: Is Nomi safe to use while breastfeeding?

Human data are insufficient to fully determine any drug-associated risk for a child during breastfeeding. Official information confirms that zolmitriptan and its active metabolite are present in human breastmilk. The potential benefits of the medicine for the mother should be weighed against the potential risks to the nursing infant.

Q: What are the signs or symptoms of Serotonin Syndrome?

Serotonin Syndrome is a rare, but serious potential risk when Nomi is taken with certain other serotonergic medicines. Signs of this condition, according to official labeling, may include changes in mental status (like confusion or hallucinations), problems with autonomic control (such as rapid heart rate or high blood pressure), and issues with neuromuscular function such as hyperreflexia (overactive reflexes).

How should Nomi be stored and disposed of?

How to Store and Dispose of Nomi (Zolmitriptan)

Storage and disposal requirements for Nomi are established by government regulatory bodies to ensure product quality and public safety.

Official Storage Conditions

Nomi tablets and nasal spray must be stored at controlled room temperature (20 C to 25 C), protecting the medication from excess heat and moisture. The tablets must be kept in the original container and maintained tightly closed. The nasal spray form includes a specific instruction to not freeze the product.

Child-Safety and Disposal

All forms of Nomi must be stored out of the sight and reach of children as a primary safety measure. The disposal of any unused or expired product must be carried out in accordance with local requirements. Regulatory guidelines advise against disposing of the medicine via wastewater or household waste unless specific drug labeling instructs otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

Equivalent of Nomi found in:

A-Z Index: